FinancialBuzz.com’s latest
The Buzz Show: Featuring Our Corporate News Recap on “Ocuphire Pharma, Inc (NASDAQ: OCUP) Surges After VEGA-1 Phase 2 Trial Met Study Endpoints In Presbyopic Patients”
Ocuphire Pharma, Inc. (NASDAQ: OCUP) surged over 40% in premarket trading after the company’s VEGA-1 Phase 2 Trial in Presbyopia Met its Primary and Secondary Endpoints.
Key secondary endpoints on visual acuity and pupil diameter showed statistical significance and the Company now plans to advance into Phase 3 registration trials.
Ocuphire is a publicly traded (NASDAQ: OCUP), clinical-stage ophthalmic biopharmaceutical company focused on developing and commercializing therapies for the treatment of several eye disorders. Ocuphire’s pipeline currently includes two small-molecule product candidates targeting front and back of the eye indications. The company’s lead product candidate, Nyxol® (0.75% phentolamine ophthalmic solution) Eye Drops, is a once-daily preservative-free e
FinancialBuzz.com’s latest
The Buzz Show: Featuring Our Corporate News Recap on “Exela Technologies, Inc. Surges Amid Providing EON Automation Platform to Health Insurance Company”
Exela Technologies, Inc. (NASDAQ: XELA) surged over 51% in premarket trading after the company announced the rollout of EON, Exela’s Robotic Process Automation platform for a large health insurance company.
This effort accelerates the digital transformation efforts for a major insurer by automating repetitive manual tasks, and is currently utilized by several customers across multiple industries including Banking, Finance & Accounting and the Public Sector.
Exela Technologies is a business process automation (BPA) leader, leveraging a global footprint and proprietary technology to provide digital transformation solutions enhancing quality, productivity, and end-user experience.
Posted on
FinancialBuzz.com’s latest
The Buzz Show: Featuring Our Corporate News Recap on “Bionano Genomics, Inc. up 6% after Becoming a Member of US Small-Cap Russell 2000® Index”
Bionano Genomics, Inc. (NASDAQ: BNGO) gained over 6% in premarket trading after the Company said it was added as a member of the US small-cap Russell 2000® Index, effective as of the Market open on June 28th.
Membership in the Russell 2000® Index, which remains in place for one year, is based on membership in the broad-market Russell 3000® Index, with the indexes widely used by investment managers and institutional investors for index funds and as benchmarks for active investment strategies.
FinancialBuzz.com’s latest
The Buzz Show: Featuring Our Corporate News Recap on “Intellia Therapeutics, Inc. Surges Following Positive Gene Editing Data”
Intellia Therapeutics, Inc. (NASDAQ: NTLA) surged over 59% in premarket trading after the Company and Regeneron Pharmaceuticals announced positive interim data from an ongoing Phase 1 clinical study of their lead in vivo genome editing candidate, NTLA-2001.
The Phase 1 study of a single-dose treatment for ATTR is evaluating the first CRISPR/Cas9-based therapy candidate to be administered systemically, via intravenous infusion, for precision editing of a gene in a target tissue in humans.
Intellia Therapeutics, a leading clinical-stage genome editing company, is developing novel, potentially curative therapeutics using CRISPR/Cas9 technology. To fully realize the transformative potential of CRISPR/Cas9, Intellia is pursuing two primary approaches. The company’s
The Buzz Show: Marin Software (NASDAQ: MRIN) New Instacart Ad Integration | Financial Buzz The Buzz Show: Marin Software (NASDAQ: MRIN) New Instacart Ad Integration financialbuzz.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from financialbuzz.com Daily Mail and Mail on Sunday newspapers.